Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)
Syndax Pharmaceuticals (SNDX) posted quarterly Non-Current Debt of $331.6 million for Q4 2024, up 2451.68% quarter-over-quarter from $13.0 million in Q2 2022.
Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024) Analysis & Trends
Syndax Pharmaceuticals' Non-Current Debt history runs 4 years deep, the most recent figure standing at $331.6 million for Q4 2024.
- In Q4 2024, Non-Current Debt changed N/A year-over-year to $331.6 million; the TTM figure through Dec 2024 stood at $331.6 million (changed N/A YoY), while the FY2024 annual figure was $331.6 million, changed N/A from the prior year.
- Non-Current Debt for Q4 2024 stood at $331.6 million, up from $13.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $331.6 million in Q4 2024, with the low at $11.0 million in Q3 2021.
- The 4-year median for Non-Current Debt is $17.8 million (2020), against an average of $45.3 million.
- Peak annual rise in Non-Current Debt reached 11.56% in 2021, while the deepest fall reached 45.07% in 2021.
- Syndax Pharmaceuticals' Non-Current Debt stood at $17.8 million in 2020, then increased by 11.56% to $19.9 million in 2021, then sank by 34.69% to $13.0 million in 2022, then soared by 2451.68% to $331.6 million in 2024.
- Business Quant data shows SNDX's Non-Current Debt at $331.6 million in Q4 2024, $13.0 million in Q2 2022, and $16.5 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 331.57 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 16.48 Mn |
| Dec 31, 2021 | 19.90 Mn |
| Sep 30, 2021 | 10.99 Mn |
| Jun 30, 2021 | 13.32 Mn |
| Mar 31, 2021 | 15.60 Mn |
| Dec 31, 2020 | 17.83 Mn |
| Sep 30, 2020 | 20.01 Mn |
| Jun 30, 2020 | 19.90 Mn |
| Mar 31, 2020 | 19.79 Mn |